HDBuzz

Huntington’s disease research news.

In plain language. Written by scientists.
For the global HD community.

Change Language
HDBuzz
  • Worms to the Rescue: Separating the Good, the Bad, and the Clumpy Huntingtin

    Worms to the Rescue: Separating the Good, the Bad, and the Clumpy Huntingtin

Latest News

  • January 2026: This Month in Huntington’s Disease Research

    January 2026: This Month in Huntington’s Disease Research

    ⏱️ 9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical FDA meeting for AMT-130, plus new insights on sleep, vaccines, and symptom management. Read the full roundup!

HDBuzz Trial Tracker

Type A Meeting FDA to Define Next Steps for AMT-130

uniQure
Expected: mid-Feb 2026

Phase 3 for SOM3355 to commence

SOM Biotech
Expected: Q4 2026

Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02

Alnylam Pharmaceuticals
Expected: 2026

GENERATION-HD2 Trial Expected to Complete

Roche
Expected: 2026

Update on Planned Phase 2/3 Study for WVE-003

Wave Life Sciences
Expected: Not disclosed

Update on Phase 1/2a Clinical Data of VO659

Vico Therapeutics
Expected: Not disclosed

Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam

Novartis/PTC Therapeutics
Expected: Not disclosed

First participant in Phase 1/2 gene therapy trial dosed

Roche
Expected: Not disclosed

First participant dosed in POINT-HD trial

Roche
Expected: Not disclosed

Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial

Skyhawk Therapeutics
Expected: Not disclosed

Previously featured

More…

Start here

New to HD Research? Click here to get an overview

Follow HDBuzz

Sign up to our monthly email summary by entering your email address on our mailing list page.

Suggest an article

Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.

Email editors@hdbuzz.net